Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07686770 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Efficacy and Safety of Immunoglobulin Plus Firsekibart in Patients With Kawasaki Disease

StatusNot Yet Recruiting
PhasePhase 2/3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Eligibility criteria shortened, about 20 wordsv3
  2. Secondary endpoints: details revised at 3 of 15 entriesv2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study evaluates the efficacy and safety of the addition of Firsekibart to standard initial treatment (intravenous immunoglobulin \[IVIG\] plus aspirin) in children with Acute Kawasaki Disease (KD) .
Trial Details
NCT Number NCT07686770
Lead Sponsor Children's Hospital of Fudan University
Collaborators: Jiangxi Province Children's Hospital
Conditions
(from sponsor)		 Kawasaki Disease
Related terms Mucocutaneous Lymph Node Syndrome
Enrollment 90 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov